论文部分内容阅读
目的:探讨肺康复训练对不同严重度稳定期慢性阻塞性肺疾病的影响。方法:选自我科于2014.4.23-2017.4.23间收集的270例稳定期慢性阻塞性肺疾病患者为研究对象,按照患者病情严度的差异,将其分为中度慢阻肺120例、重度慢阻肺80例、极重度慢阻肺70例,再次依据肺康复训练的不同,分为对照组和康复组,即对照组只采用慢阻肺常规治疗,康复组于慢阻肺常规治疗的基础上施以肺康复训练,探讨肺康复训练对不同严重度稳定期慢性阻塞性肺疾病的影响。结果:康复组患者生存质量均优于对照组,即两组患者生存质量比较中差异明显(P<0.05)。两组患者中,仅在重度和极重度慢阻肺活动耐量比较差异明显(P<0.05)。不同严重度稳定期慢阻肺患者中,仅重度慢阻肺患者急性加重次数比较差异明显(P<0.05)。结论:针对不同严重度稳定期慢性阻塞性肺疾病患者,肺康复训练均可显著改善患者生存质量、活动耐量,降低患者急性加重次数,减轻呼吸困难症状,属于高效、经济性的稳定期慢阻肺最佳治疗方案。
Objective: To investigate the effect of pulmonary rehabilitation training on chronic obstructive pulmonary disease with different severity. Methods: A total of 270 stable COPD patients collected from our department from April 2014 to March 2017 were collected from 120 patients with moderate chronic obstructive pulmonary disease (COPD) according to the severity of the patients. 80 cases of severe chronic obstructive pulmonary disease, 70 cases of extremely severe chronic obstructive pulmonary disease, again according to different types of pulmonary rehabilitation training, divided into control group and rehabilitation group, that is, the control group only with conventional COPD treatment, rehabilitation group in COPD routine treatment Based on the implementation of pulmonary rehabilitation training to explore the rehabilitation of different severity of the severity of chronic obstructive pulmonary disease. Results: The quality of life of the rehabilitation group was better than that of the control group, that is, there was significant difference in the quality of life between the two groups (P <0.05). Two groups of patients, only in severe and very severe COPD tolerance significantly (P <0.05). Among patients with chronic obstructive pulmonary disease of different severity and severe degree, the number of acute exacerbations in patients with severe chronic obstructive pulmonary disease was significantly different (P <0.05). CONCLUSION: For patients with chronic obstructive pulmonary disease of different severity and severity, pulmonary rehabilitation training can significantly improve the quality of life and activity of patients, reduce the number of exacerbations and alleviate the symptoms of dyspnea, which are both efficient and economical. The best lung treatment.